SUBSCRIBE
SUBSCRIBE

Novartis

NEWS
Novartis AG’ Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
August 31, 2017
 · 
1 min read
Novartis to Hold On to Its 33% Stake in Roche—For Now
FDA
Novartis AG Waltzes to the Finish Line With First Ever FDA Approval for CAR-T
August 30, 2017
 · 
3 min read
Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million
Drug Development
A First: Novartis AG Drug May Prevent Heart Attacks and Cut Lung Cancer Risk Too
August 28, 2017
 · 
2 min read
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Novartis AG Pays $31 Million+ for XOMA ‘s Failed Phase III Drug
August 25, 2017
 · 
3 min read
Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million
Business
Novartis AG Lures Superstar Scientist Away From UCSF
August 17, 2017
 · 
3 min read
Novartis to Hold On to Its 33% Stake in Roche—For Now
Deals
Novartis AG Boss Updates Q2 Financials and Reaffirms M&A Strategy
July 19, 2017
 · 
3 min read
Business
Novartis AG’s Long-Suffering Alcon Sees Sales Growth in Q2, Opening Door to Spin-Off IPO
July 18, 2017
 · 
1 min read
Novartis to Hold On to Its 33% Stake in Roche—For Now
Novartis AG Stocking Up on “Big-3" Arthritis Blockbusters to Get an Edge on Rivals
July 14, 2017
 · 
2 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
FDA
FDA Panel Unanimously Endorses Novartis AG’s CAR-T Leukemia Drug
July 13, 2017
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
March 30, 2026
 · 
10 min read
Press Releases
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
March 27, 2026
 · 
6 min read
Press Releases
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
March 23, 2026
 · 
5 min read
Press Releases
Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program
March 20, 2026
 · 
2 min read
Press Releases
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
March 20, 2026
 · 
6 min read
Press Releases
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
March 15, 2026
 · 
11 min read
Press Releases
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
March 6, 2026
 · 
4 min read
Press Releases
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
March 1, 2026
 · 
8 min read
Press Releases
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
March 1, 2026
 · 
4 min read
Press Releases
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
February 27, 2026
 · 
10 min read
Load More